David J Yvars Group Makes New $1.48 Million Investment in Danaher Corporation $DHR

David J Yvars Group acquired a new stake in Danaher Corporation (NYSE:DHR) during the third quarter, HoldingsChannel reports. The firm acquired 6,700 shares of the conglomerate’s stock, valued at approximately $1,484,000. Danaher accounts for 0.7% of David J Yvars Group’s holdings, making the stock its 22nd largest position.

Other institutional investors and hedge funds have also made changes to their positions in the company. EP Wealth Advisors LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $3,807,000. Puzo Michael J acquired a new stake in shares of Danaher during the second quarter worth $8,624,000. First Nebraska Trust Co acquired a new stake in shares of Danaher during the second quarter worth $14,106,000. Madison Asset Management LLC purchased a new position in Danaher in the 2nd quarter valued at $85,451,000. Finally, Colton Groome Financial Advisors LLC purchased a new position in Danaher in the 3rd quarter valued at $592,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. The Goldman Sachs Group upped their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. TD Cowen lowered their target price on shares of Danaher from $240.00 to $236.00 and set a “buy” rating on the stock in a report on Wednesday, July 22nd. Piper Sandler assumed coverage on shares of Danaher in a research note on Thursday, June 11th. They set a “neutral” rating and a $200.00 price target on the stock. Barclays increased their price target on shares of Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Guggenheim lifted their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $235.23.

Danaher Price Performance

Shares of NYSE:DHR traded up $2.69 on Friday, reaching $220.15. 3,934,329 shares of the company were exchanged, compared to its average volume of 4,457,726. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80. The firm has a market cap of $154.76 billion, a price-to-earnings ratio of 39.10, a price-to-earnings-growth ratio of 2.72 and a beta of 0.76. The company has a 50-day moving average of $210.88 and a 200-day moving average of $194.44.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The firm had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.77 earnings per share. Equities analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.